Dynamic, open, personal: From today forward, these attributes will be the new public face of the Bayer brand.

• · Comprehensive study recently published in Current Biology
  · Research findings will improve Bayer’s ability to develop new selective insecticides

Group sales increased by 1.5 percent (Fx & portfolio adj.) to 35.015 billion euros / Another record year for Pharmaceuticals / Weak business development at Consumer Health / Crop Science business down against prior year due to situation in Brazil – measures taking effect / EBITDA before special items level year on year at 9.288 billion euros / Net income raised by 61.9 percent to 7.336 billion euros / Core earnings per share increased by 1.0 percent to 6.74 euros / Covestro deconsolidated – additional cash inflows of 4.7 billion euros / Monsanto acquisition expected to close in second quarter of 2018 / Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects

• Toegang tot samenvattingen van studies over de veiligheid van gewasbeschermingsmiddelen
• Streven naar een open en transparante dialoog met de samenleving
• Ondersteuning van de autoriteiten bij het afhandelen van dataverzoeken

· Brand encompasses all Bayer Digital Farming solutions
· Commitment to sustainability and transparency
· Currently over 250.000 users in more than 60 countries with rapid further expansion

Covestro deconsolidated / Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million / EBITDA before special items up by 4.1 percent to EUR 2,204 million / Sales and earnings growth at Pharmaceuticals / Consumer Health business weak, as expected / Sales gains at Crop Science and Animal Health / Net income of EUR 3,881 million including Covestro book profit / Core earnings per share at EUR 1.47 (minus 3.9 percent) / Group outlook for 2017 confirmed based on change in structure

Nurturing global change agents